Skip to content
Triangle logo TriangleGet started
← Malignant Kidney Neoplasm

NCT00365768 · STUDY IN CONTEXT

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Incidence of Vincristine-induced Peripheral Neuropathy

Source null

→

secondary · POSTED

Number of Participants With Progression of Neuropathy

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-malignant-kidney-neoplasm
nct id
NCT00365768
trial label
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
2
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    outcome key
    om-0000
    source section id
    NCT00365768-om-0000
    source outcome index
    0
    endpoint
    Incidence of Vincristine-induced Peripheral Neuropathy
    endpoint definition
    Incidence of Vincristine-induced Peripheral Neuropathy
    time origin
    Up to 30 weeks from baseline while on Vincristine treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    outcome key
    om-0001
    source section id
    NCT00365768-om-0001
    source outcome index
    1
    endpoint
    Number of Participants With Progression of Neuropathy
    endpoint definition
    Number of Participants With Progression of Neuropathy
    time origin
    42 days
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Arm I: Glutamine
    regimen
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21. Glutamine: Administered orally twice daily for 21 days
    analyzed count
    24
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00365768-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Arm II: Placebo
    regimen
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21. Placebo: Administered orally twice daily for 21 days
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00365768-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Arm I: Glutamine
    regimen
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21. Glutamine: Administered orally twice daily for 21 days
    analyzed count
    24
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00365768-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Arm II: Placebo
    regimen
    Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21. Placebo: Administered orally twice daily for 21 days
    analyzed count
    25
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00365768-om-0001#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    harm key
    EG000
    source section id
    NCT00365768-ae
    event group key
    EG000
    event group label
    Arm I: Glutamine
    serious affected
    0
    serious at risk
    24
    other affected
    0
    other at risk
    24
    frequency threshold
    0
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-malignant-kidney-neoplasm
    nct id
    NCT00365768
    harm key
    EG001
    source section id
    NCT00365768-ae
    event group key
    EG001
    event group label
    Arm II
    serious affected
    0
    serious at risk
    25
    other affected
    0
    other at risk
    25
    frequency threshold
    0
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice